+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oncology Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5292711
  • Report
  • February 2021
  • Region: Global
  • 300 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Novartis AG
  • Takeda Pharmaceticals
  • MORE
Oncology Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global oncology drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the oncology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Oncology Drugs market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider oncology drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The oncology drugs market section of the report gives context. It compares the oncology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, oncology drugs indicators comparison.
Scope

Markets Covered:
1) By Type: Lung Cancer Drugs; Pancreatic Cancer Drugs; Breast Cancer Drugs; Prostate Cancer Drugs; Ovarian Cancer Drugs; Colorectal Cancer Drugs; Gastric Cancer Drugs; Kidney Cancer Drugs; Brain Tumor Drugs; Thyroid Cancer Drugs; Skin Cancer Drugs; Bladder Cancer Drugs; Cervical Cancer Drugs; Blood Cancer Drugs; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Companies Mentioned: F. Hoffmann-La Roche Ltd; Novartis AG; Gilead Sciences Inc; Bayer AG; Takeda Pharmaceticals

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, oncology drugs indicators comparison.

Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Novartis AG
  • Takeda Pharmaceticals
  • MORE
1. Executive Summary

2. Report Structure

3. Oncology Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations

4. Oncology Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products

5. Oncology Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers

6. Oncology Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth

7. Oncology Drugs Market Trends and Strategies

8. Impact of COVID-19 on Oncology Drugs

9. Oncology Drugs Market Size and Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.2.1. Drivers of the Market
9.2.2. Restraints on the Market
9.3. Forecast Market Growth, Value ($ Billion)
9.3.1. Drivers of the Market
9.3.2. Restraints on the Market

10. Oncology Drugs Market Regional Analysis
10.1. Global Oncology Drugs Market, 2020, by Region, Value ($ Billion)
10.2. Global Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
10.3. Global Oncology Drugs Market, Growth and Market Share Comparison, by Region

11. Oncology Drugs Market Segmentation
11.1. Global Oncology Drugs Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Lung Cancer Drugs
  • Pancreatic Cancer Drugs
  • Breast Cancer Drugs
  • Prostate Cancer Drugs
  • Ovarian Cancer Drugs
  • Colorectal Cancer Drugs
  • Gastric Cancer Drugs
  • Kidney Cancer Drugs
  • Brain Tumor Drugs
  • Thyroid Cancer Drugs
  • Skin Cancer Drugs
  • Bladder Cancer Drugs
  • Cervical Cancer Drugs
  • Blood Cancer Drugs
  • Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
11.2. Global Oncology Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies/ Drug Stores
  • Others
11.3. Global Oncology Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Oral
  • Parenteral
  • Others
11.4. Global Oncology Drugs Market, Segmentation by Drug Classification, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Branded Drugs
  • Generic Drugs
11.5. Global Oncology Drugs Market, Segmentation by Mode of Purchase, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Prescription-Based Drugs
  • Over-The-Counter Drugs
12. Oncology Drugs Market Metrics
12.1. Oncology Drugs Market Size, Percentage of GDP, 2015-2025, Global
12.2. Per Capita Average Oncology Drugs Market Expenditure, 2015-2025, Global

13. Asia-Pacific Oncology Drugs Market
13.1. Asia-Pacific Oncology Drugs Market Overview
  • Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
13.2. Asia-Pacific, Oncology Drugs Market, 2020, by Country, Value ($ Billion)
13.3. Asia-Pacific, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
13.4. Asia-Pacific, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
13.5. Asia-Pacific, Oncology Drugs Market Metrics
13.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2025, Asia-Pacific Countries
13.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2020, Asia-Pacific Countries
13.6. Asia-Pacific Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7. Asia-Pacific Oncology Drugs Market: Country Analysis
13.7.1. China Oncology Drugs Market
13.7.1.1. China Oncology Drugs Market Overview
13.7.1.2. China Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.1.3. China Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2. Australia Oncology Drugs Market
13.7.2.1. Australia Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2.2. Australia Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.3. Hong Kong Oncology Drugs Market
13.7.3.1. Hong Kong Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4. India Oncology Drugs Market
13.7.4.1. India Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4.2. India Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5. Indonesia Oncology Drugs Market
13.7.5.1. Indonesia Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5.2. Indonesia Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6. Japan Oncology Drugs Market
13.7.6.1. Japan Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6.2. Japan Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.7. Malaysia Oncology Drugs Market
13.7.7.1. Malaysia Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.8. New Zealand Oncology Drugs Market
13.7.8.1. New Zealand Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.9. Philippines Oncology Drugs Market
13.7.9.1. Philippines Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.10. Singapore Oncology Drugs Market
13.7.10.1. Singapore Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11. South Korea Oncology Drugs Market
13.7.11.1. South Korea Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11.2. South Korea Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.12. Thailand Oncology Drugs Market
13.7.12.1. Thailand Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.13. Vietnam Oncology Drugs Market
13.7.13.1. Vietnam Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

14. Western Europe Oncology Drugs Market
14.1. Western Europe Oncology Drugs Market Overview
14.2. Western Europe, Oncology Drugs Market, 2020, by Country, Value ($ Billion)
14.3. Western Europe, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
14.4. Western Europe, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
14.5. Western Europe, Oncology Drugs Market Metrics
14.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2025, Western Europe Countries
14.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2020, Western Europe Countries
14.6. Western Europe Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7. Western Europe Oncology Drugs Market: Country Analysis
14.7.1. Austria Oncology Drugs Market
14.7.1.1. Austria Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.2. Belgium Oncology Drugs Market
14.7.2.1. Belgium Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.3. Denmark Oncology Drugs Market
14.7.3.1. Denmark Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.4. Finland Oncology Drugs Market
14.7.4.1. Finland Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5. France Oncology Drugs Market
14.7.5.1. France Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5.2. France Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6. Germany Oncology Drugs Market
14.7.6.1. Germany Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6.2. Germany Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.7. Ireland Oncology Drugs Market
14.7.7.1. Ireland Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.8. Italy Oncology Drugs Market
14.7.8.1. Italy Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.9. Netherlands Oncology Drugs Market
14.7.9.1. Netherlands Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.10. Norway Oncology Drugs Market
14.7.10.1. Norway Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.11. Portugal Oncology Drugs Market
14.7.11.1. Portugal Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.12. Spain Oncology Drugs Market
14.7.12.1. Spain Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.13. Sweden Oncology Drugs Market
14.7.13.1. Sweden Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.14. Switzerland Oncology Drugs Market
14.7.14.1. Switzerland Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15. UK Oncology Drugs Market
14.7.15.1. UK Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15.2. UK Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

15. Eastern Europe Oncology Drugs Market
15.1. Eastern Europe Oncology Drugs Market Overview
15.2. Eastern Europe, Oncology Drugs Market, 2020, by Country, Value ($ Billion)
15.3. Eastern Europe, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
15.4. Eastern Europe, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
15.5. Eastern Europe, Oncology Drugs Market Metrics
15.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2025, Eastern Europe Countries
15.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2020, Eastern Europe Countries
15.6. Eastern Europe Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7. Eastern Europe Oncology Drugs Market: Country Analysis
15.7.1. Czech Republic Oncology Drugs Market,
15.7.1.1. Czech Republic Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.2. Poland Oncology Drugs Market
15.7.2.1. Poland Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.3. Romania Oncology Drugs Market
15.7.3.1. Romania Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4. Russia Oncology Drugs Market
15.7.4.1. Russia Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4.2. Russia Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

16. North America Oncology Drugs Market
16.1. North America Oncology Drugs Market Overview
16.2. North America, Oncology Drugs Market, 2020, by Country, Value ($ Billion)
16.3. North America, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
16.4. North America, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
16.5. North America, Oncology Drugs Market Metrics
16.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2025, North America Countries
16.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2020, North America Countries
16.6. North America Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7. North America Oncology Drugs Market: Country Analysis
16.7.1. Canada Oncology Drugs Market
16.7.1.1. Canada Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.2. Mexico Oncology Drugs Market
16.7.2.1. Mexico Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3. USA Oncology Drugs Market
16.7.3.1. USA Oncology Drugs Market Overview
16.7.3.2. USA Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3.3. USA Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

17. South America Oncology Drugs Market
17.1. South America Oncology Drugs Market Overview
17.2. South America, Oncology Drugs Market, 2020, by Country, Value ($ Billion)
17.3. South America, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
17.4. South America, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
17.5. South America, Oncology Drugs Market Metrics
17.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2025, South America Countries
17.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2020, South America Countries
17.6. South America Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7. South America Oncology Drugs Market: Country Analysis
17.7.1. Argentina Oncology Drugs Market
17.7.1.1. Argentina Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2. Brazil Oncology Drugs Market
17.7.1.1. Brazil Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2.2. Brazil Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.3. Chile Oncology Drugs Market
17.7.3.1. Chile Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.4. Colombia Oncology Drugs Market
17.7.4.1. Colombia Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.5. Peru Oncology Drugs Market
17.7.5.1. Peru Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.6. Venezuela Oncology Drugs Market
17.7.6.1. Venezuela Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

18. Middle East Oncology Drugs Market
18.1. Middle East Oncology Drugs Market Overview
18.2. Middle East, Oncology Drugs Market, 2020, by Country, Value ($ Billion)
18.3. Middle East, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
18.4. Middle East, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
18.5. Middle East, Oncology Drugs Market Metrics
18.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2025, Middle East Countries
18.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2020, Middle East Countries
18.6. Middle East Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7. Middle East Oncology Drugs Market: Country Analysis
18.7.1. Saudi Arabia Oncology Drugs Market
18.7.1.1. Saudi Arabia Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.2. Israel Oncology Drugs Market
18.7.2.1. Israel Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.3. Turkey Oncology Drugs Market
18.7.3.1. Turkey Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.4. UAE Oncology Drugs Market
18.7.4.1. UAE Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

19. Africa Oncology Drugs Market
19.1. Africa Oncology Drugs Market Overview
19.2. Africa, Oncology Drugs Market, 2020, by Country, Value ($ Billion)
19.3. Africa, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
19.4. Africa, Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
19.5. Africa, Oncology Drugs Market Metrics
19.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2025, Africa Countries
19.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2020, Africa Countries
19.6. Africa Oncology Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7. Africa Oncology Drugs Market: Country Analysis
19.7.1. Egypt Oncology Drugs Market
19.7.1.1. Egypt Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.2. Nigeria Oncology Drugs Market
19.7.2.1. Nigeria Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.3. South Africa Oncology Drugs Market
19.7.3.1. South Africa Oncology Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

20. Oncology Drugs Market Competitive Landscape
20.1. Competitive Market Overview
20.2. Market Shares
20.3. Company Profiles
20.3.1. F. Hoffmann-La Roche Ltd
20.3.1.1. Company Overview
20.3.1.2. Products and Services
20.3.1.3. Strategy
20.3.1.4. Financial Performance
20.3.2. Novartis AG
20.3.2.1. Company Overview
20.3.2.2. Products and Services
20.3.2.3. Strategy
20.3.2.4. Financial Performance
20.3.3. Gilead Sciences Inc
20.3.3.1. Company Overview
20.3.3.2. Products and Services
20.3.3.3. Strategy
20.3.3.4. Financial Performance
20.3.4. Bayer AG
20.3.4.1. Company Overview
20.3.4.2. Products and Services
20.3.4.3. Strategy
20.3.4.4. Financial Performance
20.3.5. Takeda Pharmaceticals
20.3.5.1. Company Overview
20.3.5.2. Products and Services
20.3.5.3. Strategy
20.3.5.4. Financial Performance

21. Key Mergers and Acquisitions in the Oncology Drugs Market

22. Market Background: Pharmaceutical Drugs Market
22.1. Pharmaceutical Drugs Market Characteristics
22.2. Pharmaceutical Drugs Market Historic and Forecast, 2015-2020, 2020-2025F, 2030F Growth, by Segment, Value ($ Billion), Global
22.3. Global Pharmaceutical Drugs Market, 2020, by Region, Value ($ Billion)
22.4. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
22.5. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Segmentation by Type, Value ($ Billion)

23. Recommendations
23.1. Global Oncology Drugs Market in 2025 - Growth Countries
23.2. Global Oncology Drugs Market in 2025 - Growth Segments
23.3. Global Oncology Drugs Market in 2025 - Growth Strategies

24. Appendix
24.1. NAICS Definitions of Industry Covered in This Report
24.2. Abbreviations
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher

25. Copyright and Disclaimer
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Novartis AG
  • Takeda Pharmaceticals
  • MORE
Major companies in the oncology drugs market include F. Hoffmann-La Roche Ltd; Novartis AG; Gilead Sciences Inc; Bayer AG and Takeda Pharmaceticals.

The global oncology drugs market is expected to grow from $80.92 billion in 2020 to $84.38 billion in 2021 at a compound annual growth rate (CAGR) of 4.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $112.14 billion in 2025 at a CAGR of 7%.

The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, brain tumor, and other different cancer types. The oncology drugs market is segmented into lung cancer; pancreatic cancer; breast cancer; prostate cancer; ovarian cancer; colorectal cancer; gastric cancer; kidney cancer; brain tumor; thyroid cancer; skin cancer; bladder cancer; cervical cancer; blood cancer; and others (kaposi sarcoma, aids-related lymphoma, anal cancer, bone cancer, retinoblastoma, testicular cancer, hepatocellular (liver) cancer, mouth cancer, neuroblastoma).

North America was the largest region in the global oncology drugs market, accounting for 35% of the market in 2020. Asia Pacific was the second largest region accounting for 35% of the global oncology drugs market. Africa was the smallest region in the global oncology drugs market.

Companies in the oncology drug market are investing in targeted therapy, which has proven to be less toxic compared to traditional treatment options. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Companies in oncology market such as Pfizer, Novartis and Abbvie have understood the importance of this treatment method and are increasingly investing in it. According to a report by QuintilesIMS, 87% of the drugs currently in pipeline constitute of targeted therapy drugs.

Companies in the oncology drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major oncology drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For example, Johnson and Johnson has recently entered into an agreement with BenevolentAI, a UK-based start-up, to mine data for designing new oncology drugs.

The outbreak of Coronavirus disease (COVID-19) has acted as a significant restraint on the oncology drugs market in 2020 as supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across countries. COVID 19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and spread globally including Western Europe, North America and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of 'lock down' and the outbreak is expected to continue to have a negative impact on businesses throughout 2020 and into 2021. Pharmaceutical markets such as this one have been relatively unaffected however due to continued availability of drugs during government lock downs and inelasticity of demand. It is expected that the oncology market will recover from the shock across the forecast period as it is a 'black swan' event and not related to ongoing or fundamental weaknesses in the market or the global economy.
Note: Product cover images may vary from those shown
4 of 5
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Gilead Sciences Inc
  • Bayer AG
  • Takeda Pharmaceticals
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll